Loading...
•
Dec 31, 2019
Sage Q4 2019 Earnings Report
Sage reported Q4 2019 financial results, highlighted pipeline and business progress.
Key Takeaways
Sage Therapeutics reported $2.0 million in revenues from ZULRESSO sales for the fourth quarter of 2019. The company is evaluating the path forward for the zuranolone (SAGE-217) Landscape Program and plans to continue expanding its Neurology and Neuropsychiatry franchises with additional studies in 2020.
ZULRESSO™ (brexanolone) CIV injection net revenues were $2M for the fourth quarter.
Evaluating path forward for the zuranolone (SAGE-217) Landscape Program.
Continued expansion of Neurology and Neuropsychiatry franchises with planned initiation of additional SAGE-324 and SAGE-718 studies in 2020.
More than 175 healthcare facilities were ZULRESSO REMS certified across 75 of the top 140 Metropolitan Statistical Areas in the U.S.
Revenue by Segment
Forward Guidance
Sage expects ZULRESSO revenue growth will be modest over the next couple of quarters with an increase in the rate of growth of ZULRESSO revenue anticipated in the second half of 2020.
Positive Outlook
- Increase in the number of treatment-ready sites, including larger hospitals administering ZULRESSO to treat women with PPD.
- Increase in the volume of patients treated at existing sites.
- Sage is guiding large sites through the steps necessary to become treatment-ready.
- Supporting hospital administrations’ efforts to reduce the complexity of those steps.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...